purified and further processed by ultrafiltration. Analytical studies have shown that the current manufacturing processes are capable of removing significant amounts of extraneous proteins and result in a reduction of factor Va light chain content levels below the limit of detection of the Western blot assay (less than 92 ng/mL, when reconstituted as directed). However, the clinical significance of this reduction of factor Va-related antigen is unknown.
The US FDA approval of the revised labeling regarding the purity of Thrombin JMI is a testimonial for the advanced methods that can be used to purify biologicals, such as bovine thrombin, to remove contaminants, which may lead to the generation of antibodies or may trigger other adverse reactions. Although the removal of bovine factor V, factor Va and/or their fragments from the product has been shown, it is highly likely that other potential contaminants and carryover products are also removed in this additional purification step. Therefore, a comparison of the crude thrombin and the 2 purified versions for other potential contaminants, including prothrombin, factors VII and X, may also be helpful because bovine plasma is used as the starting material for the preparation of the crude thrombin. The purified Thrombin JMI will likely show a relatively improved safety profile with much lesser immunogenic potential. Despite the fact that the reported hemostatic abnormalities with the use of this product since the 1940s are relatively rare, 2-6 the improved product may show an even lesser prevalence of these reported adverse reactions.
It should remain clear that despite improved purification processes, some biological products may retain inherent immunologic properties leading to the generation of antibodies, as has been the case with many of the highly purified drugs such as recombinant hirudin, aprotinin, and recombinant B ovine thrombin is widely used as a topical hemostatic agent in various surgical procedures. To date, more than 10 million individuals have been exposed to this product. Rare case reports of adverse reactions such as antigenic reactions and apparent generation of antibodies leading to hemostatic disruption have been reported. Isolated reports on the presence of factor Va-related antigen and other contaminant proteins have also been made available. Additionally, case reports have commented on the generation of antibodies to other human coagulation factors. However, bovine thrombin has been remarkably safe than other biological products, such as aprotinin, unfractionated heparin, and erythropoietin.
The article by Terrab, et al 1 in this issue of Clinical and Applied Thrombosis/Hemostasis reports on the inclusion of a membrane-filtration step in the manufacturing process, which is performed to remove viruses from chromatographically purified bovine thrombin. It has been found that this step also results in the effective removal of extraneous protein contaminants, in particular factor V, factor Va and/or their fragments from the product. 1 On review of the data summated for this purification process, the US Food and Drug Administration (FDA) has approved a revised labeling for Thrombin JMI (Thrombin, topical bovine, United States Pharmacopenia) to recognize the reduced factor Va light chain content (considered to be a factor for the immunogenic response). The revised labeling states that Thrombin JMI has been chromatographically erythropoietin. Therefore, despite the purified and homogeneous nature of the recombinant proteins, innate immunologic effects can be shown in animal studies and in clinical trials.
On January 17, 2008, the US FDA approved a recombinant version of human thrombin (Recothrom Thrombin), topical (recombinant) for sale. Although Recothrom is a plasma-free product, it is produced by the activation of recombinant prethrombin via nonphysiologic enzymes derived from nonhuman sources (venoms). This product is claimed to be equivalent to human thrombin and reportedly does not exhibit any significant immunogenic responses. However, the clinical experience with this product is small and its immunogenic potential and adverse reactions will be known only after wider use.
The US FDA is prudent in its mandate to require additional information on the potential immunogenic effects of biological products, including recombinant versions of human proteins such as factor VIII and thrombin. Now that 3 versions of topical hemostatic products representing purified bovine thrombin, plasma-derived human thrombin, and recombinant thrombin are available, it will be important to follow the safety and efficacy profiles of each product during their clinical use irrespective of their origin. All 3 products are apparently highly purified and exhibit structural specificity. However, each may still have a potential to evoke an immunogenic response. From the current publication, it should be appreciated that improved methodologies for protein purification exist, and these can be useful to remove potential contaminants from biologicals to minimize adverse reactions.
